# PARKIN R42P Research Report **Protein:** PARKIN R42P **Variant:** R42P **UniProt ID:** O60260 **Disease Association:** Parkinson's disease **Report Generated:** 2026-07-27 18:22 UTC **AlphaFold Confidence (pLDDT):** 73.0% **Structure Folded:** 2026-07-15 --- ## Structure Summary PARKIN is a protein that helps remove damaged mitochondria (the cell's power plants) in brain cells, and mutations in PARKIN cause early-onset Parkinson's disease. The R42P variant, classified as pathogenic by clinical experts, replaces an arginine amino acid with proline at position 42, which is predicted to disrupt the protein's structure with moderate confidence (73% average). This rare mutation, found in approximately 1 in 22,000 chromosomes, likely impairs PARKIN's ability to protect dopaminergic neurons from mitochondrial damage, contributing to the selective cell death that causes Parkinson's symptoms. --- PARKIN (encoded by the PRKN gene) functions as an E3 ubiquitin ligase that plays a critical role in mitochondrial quality control through a pathway involving PINK1 (PTEN-induced kinase 1). When mitochondria become damaged, PINK1 accumulates on their outer membrane and phosphorylates both ubiquitin and PARKIN at serine 65, activating PARKIN's enzymatic activity [4] [6]. This activated PARKIN then tags damaged mitochondria with ubiquitin chains, marking them for degradation through autophagy (mitophagy). Loss-of-function mutations in PARKIN are a primary cause of autosomal recessive early-onset Parkinson's disease, and the protein also regulates inflammatory cell death pathways that contribute to dopaminergic neuron loss [2]. The R42P variant involves substitution of arginine (a flexible, positively charged amino acid) with proline (a rigid amino acid that disrupts protein structure) at position 42. This mutation is classified as pathogenic or likely pathogenic by multiple clinical expert panels in ClinVar, based on established criteria. The variant is rare in the general population, appearing in approximately 65 out of 1.46 million chromosomes examined (frequency of 0.0000445), which is consistent with a disease-causing mutation rather than a benign variation. The evolutionary history of PRKN shows evidence of both positive selection and strong functional constraint, particularly at disease-associated sites, indicating that even small changes can have significant functional consequences [3]. Structural prediction using AlphaFold2 generated a model with an average confidence score (pLDDT) of 73%, which falls in the moderate confidence range. This confidence level suggests that while the overall fold is likely correct, specific structural details and the precise positioning of some regions remain uncertain. The substitution of arginine with proline at position 42 is particularly concerning because proline acts as a "structure breaker" that can disrupt alpha helices and beta sheets. However, the moderate confidence score means we should interpret specific structural predictions around this site with appropriate caution, and experimental validation would be needed to confirm the exact structural consequences. The clinical significance of R42P likely stems from disruption of PARKIN's role in the PINK1-PARKIN mitochondrial quality control pathway. Studies have shown that PARKIN dysfunction leads to accumulation of damaged mitochondria, increased oxidative stress, and disruption of cellular calcium homeostasis [7] [8]. Recent research demonstrates that PARKIN also regulates NLRP3 degradation through chaperone-mediated autophagy, suppressing inflammatory cell death (PANoptosis) that contributes to dopaminergic neuron loss in the substantia nigra [2]. The selective vulnerability of dopaminergic neurons in Parkinson's disease appears to connect to differential expression of mitochondrial genes in these cells, making them particularly sensitive to PARKIN dysfunction [1]. While PARKIN mutations typically cause early-onset disease, some genetic variants (such as PARK2 mutations) can present with later onset and phenotypic variability [5], though the R42P variant's pathogenic classification suggests it likely causes significant functional impairment. ## Works Cited [1] Vulinovic et al. (2026). Selective vulnerability of dopaminergic neurons in Parkinson's disease connects PRKN and differential expression of CHCHD2 and GPNMB. Cell death & disease. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42248828/) [2] Zheng et al. (2026). Parkin regulates NLRP3 degradation through chaperone-mediated autophagy to suppress PANoptosis and protect dopaminergic neurons in Parkinson's disease. Journal of neuroinflammation. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42021324/) [3] Cagliani et al. (2026). Evolutionary history of LRRK2 and PRKN in leprosy and Parkinson's disease. NPJ genomic medicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42436173/) [4] Dan et al. (2025). Mechanisms Associated with PINK1 Variants in Parkinson's Disease. F1000Research. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42368330/) [5] Paleare et al. (2026). Ozzy Osbourne and Parkinson's disease: from darkness to awareness. Arquivos de neuro-psiquiatria. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42349862/) [6] Markham et al. (2026). miRNA family miR-29 inhibits PINK1-PRKN signaling via ATG9A. Molecular neurodegeneration advances. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42327715/) [7] Bartalis et al. (2026). Miro1 mutations disrupt cellular calcium homeostasis via dysregulation of mitochondria-ER-contact-sites, rendering iPSC-derived neurons more susceptible to lipid peroxidation. Neurobiology of disease. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42314863/) [8] Zientara et al. (2026). PARK(ing) time-How park deficiency affects the biological clock in a Drosophila model of Parkinson's disease. FEBS letters. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42299891/) ## Similar Research **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Activation of endogenous PRKN by structural derepression is linked to increased turnover of the E3 ubiquitin ligase.** Fiesel et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40624741/) **Synergism of IP3R and Parkin mutants identifies mitochondrial stress as an early feature of Parkinson's disease.** Dileep et al. (2026) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41235839/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease.** Menozzi et al. (2026) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41569009/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | Young adult-onset Parkinsonism | 0.836 | literature, animal_model, genetic_association, genetic_literature | | young-onset Parkinson disease | 0.603 | literature, genetic_association | | lung cancer | 0.577 | literature, genetic_association | | ovarian cancer | 0.566 | literature, genetic_association | | Dystonia | 0.517 | literature, animal_model, genetic_literature | | Parkinson disease | 0.483 | literature, genetic_association, genetic_literature | | diabetes mellitus | 0.418 | literature, genetic_association | | type 2 diabetes mellitus | 0.387 | literature, genetic_association | | Abnormality of the skeletal system | 0.375 | genetic_association | | Parkinson disease 12 | 0.370 | genetic_association | *...and 1220 more associations* --- ## AI Research Brief # Research Brief: PARKIN R42P Variant ## Pathogenic Mechanisms The PARKIN R42P variant involves substitution of arginine (a charged, bulky residue) with proline (a rigid, helix-breaking residue) at position 42. This amino acid change likely disrupts local protein structure, as proline's unique conformational constraints can destabilize secondary structure elements and alter protein folding dynamics. PARKIN functions as an E3 ubiquitin ligase critical for mitophagy and cellular quality control, with known molecular functions including actin binding, beta-catenin binding, and cullin family protein binding. The R42P mutation may compromise these protein-protein interactions essential for PARKIN's role in mitochondrial homeostasis. Given PARKIN's involvement in biological processes including aggresome assembly and amyloid fibril formation, structural perturbations from R42P could impair the protein's ability to target misfolded proteins for degradation. The variant's proximity to the N-terminus suggests potential interference with PARKIN's interactions with key partners such as PINK1, SNCA (α-synuclein), and HSPA8, which are central to the mitophagy pathway and Parkinson's disease (PD) pathogenesis. ## Clinical Significance While specific clinical data for R42P is limited in the provided findings, PARKIN variants are well-established causes of early-onset Parkinson's disease with autosomal recessive inheritance. PRKN mutations represent one of the most common genetic causes of familial PD, typically presenting with distinctive clinical features including earlier age of onset, slower progression, and good levodopa responsiveness. The pathogenic potential of R42P is supported by the severe nature of the amino acid substitution—replacing a positively charged, flexible arginine with a conformationally rigid proline likely compromises protein stability and function. Comprehensive genetic testing, including long-read sequencing approaches, is increasingly important for detecting PARKIN variants. Emerging biomarker strategies measuring blood Parkin protein levels show promise for diagnosis and disease monitoring, which could prove valuable for assessing the functional impact of variants like R42P. ## Therapeutic Landscape Analysis reveals aggregation hotspots in PARKIN's N-terminal region (residues 1-5, score: 0.78), suggesting this domain is prone to misfolding and aggregation. The candidate peptide CP-PARKIN-001 has been computationally generated to target this aggregation-prone region (residues 1-5). The therapeutic rationale centers on preventing or reversing protein aggregation that may be exacerbated by the R42P mutation's destabilizing effects. Since the R42P variant at position 42 is relatively close to this identified hotspot, the mutation may enhance aggregation propensity in this critical N-terminal domain. Peptide-based interventions targeting this region could serve dual purposes: stabilizing the native PARKIN structure and preventing pathological aggregation. However, no specific peptide inhibitors with published literature (PMIDs) are currently available for the R42P variant specifically, indicating an opportunity for targeted therapeutic development. ## Research Directions Critical knowledge gaps exist regarding the R42P variant that warrant investigation. First, structural characterization using techniques such as X-ray crystallography or cryo-EM would definitively establish how R42P affects PARKIN's tertiary structure and domain organization. AlphaFold modeling (8 structures identified) provides a computational foundation, but experimental validation is essential. Second, functional studies should assess whether R42P impairs E3 ligase activity, substrate recognition, or interactions with PINK1 and other mitophagy pathway components. Third, aggregation propensity studies would clarify whether R42P enhances protein misfolding and whether CP-PARKIN-001 or derivative peptides can rescue this phenotype. Fourth, clinical-genetic correlation studies examining R42P carriers' phenotypes, disease progression, and treatment responses would inform genetic counseling and precision medicine approaches. Finally, exploring whether blood-based Parkin biomarkers can detect functional deficits in R42P carriers would advance non-invasive diagnostic capabilities. These investigations would bridge the gap between variant identification and mechanistic understanding, ultimately enabling targeted therapeutic strategies for R42P and related PARKIN variants. --- ## Agent Findings ### Literature (1) - **2026-07-15:** These papers are highly relevant for understanding PRKN/Parkin variants in Parkinson's disease, though none specifically address the R42P mutation. They provide critical insights into Parkin protein activation mechanisms, structural mutation effects, diagnostic biomarkers, and the genetic architecture of PRKN-related parkinsonism including detection methods for complex variants. This knowledge is essential for understanding how any PRKN mutation, including R42P, might affect protein function and disease pathogenesis. ### Clinical (1) - **2026-07-15:** ### Structural (1) - **2026-07-16:** AlphaFold structure update: Baseline check: 8 structure(s) found ### Synthesis (1) - **2026-07-16:** Synthesis of 5 findings (clinical, literature, peptides, structural, supplements): The PARKIN R42P variant represents a structurally significant mutation where arginine is replaced by... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)